Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.
Identifieur interne : 001536 ( PubMed/Corpus ); précédent : 001535; suivant : 001537Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.
Auteurs : E. Courty ; F. Durif ; M. Zenut ; P. Courty ; J. LavarenneSource :
- Clinical neuropharmacology [ 0362-5664 ] ; 1997.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Apomorphine (administration & dosage), Apomorphine (adverse effects), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Drug Overdose, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Self Administration, Sexual Dysfunctions, Psychological (chemically induced).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Apomorphine, Dopamine Agonists.
- chemical , adverse effects : Antiparkinson Agents, Apomorphine, Dopamine Agonists.
- chemically induced : Sexual Dysfunctions, Psychological.
- drug therapy : Parkinson Disease.
- Aged, Drug Overdose, Humans, Male, Middle Aged, Self Administration.
Abstract
A similar pattern of psychosexual disorders has been observed after long-term treatment with levodopa therapy in four male parkinsonian patients treated with apomorphine for severe on-off motor fluctuations. An acute episode in each case had led them to the hospital in the context of a psychiatric emergency (after punishable sexual acts in two cases). In each case, this episode had been preceded by an increase of self-administered apomorphine, whereas other antiparkinsonian drugs remained unchanged. Questioning had revealed psychosexual disturbances as early as the onset of apomorphine treatment, which tended to progressively worsen with the number of apomorphine daily doses. A decrease in the dosage of apomorphine had been followed by the improvement of the psychiatric condition without worsening of the motor status. Recurrence of psychiatric disorders with similar features had been observed when two patients again increased the number of apomorphine daily injections. The absence of somatic manifestations when apomorphine treatment was withdrawn or reduced, with persistence of psychosexual disturbances, could suggest a psychological dependence from the drug.
PubMed: 9099466
Links to Exploration step
pubmed:9099466Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.</title><author><name sortKey="Courty, E" sort="Courty, E" uniqKey="Courty E" first="E" last="Courty">E. Courty</name><affiliation><nlm:affiliation>Department of Psychiatry, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Zenut, M" sort="Zenut, M" uniqKey="Zenut M" first="M" last="Zenut">M. Zenut</name></author><author><name sortKey="Courty, P" sort="Courty, P" uniqKey="Courty P" first="P" last="Courty">P. Courty</name></author><author><name sortKey="Lavarenne, J" sort="Lavarenne, J" uniqKey="Lavarenne J" first="J" last="Lavarenne">J. Lavarenne</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9099466</idno><idno type="pmid">9099466</idno><idno type="wicri:Area/PubMed/Corpus">001536</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001536</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.</title><author><name sortKey="Courty, E" sort="Courty, E" uniqKey="Courty E" first="E" last="Courty">E. Courty</name><affiliation><nlm:affiliation>Department of Psychiatry, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Zenut, M" sort="Zenut, M" uniqKey="Zenut M" first="M" last="Zenut">M. Zenut</name></author><author><name sortKey="Courty, P" sort="Courty, P" uniqKey="Courty P" first="P" last="Courty">P. Courty</name></author><author><name sortKey="Lavarenne, J" sort="Lavarenne, J" uniqKey="Lavarenne J" first="J" last="Lavarenne">J. Lavarenne</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (adverse effects)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Drug Overdose</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Self Administration</term><term>Sexual Dysfunctions, Psychological (chemically induced)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Sexual Dysfunctions, Psychological</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Overdose</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Self Administration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A similar pattern of psychosexual disorders has been observed after long-term treatment with levodopa therapy in four male parkinsonian patients treated with apomorphine for severe on-off motor fluctuations. An acute episode in each case had led them to the hospital in the context of a psychiatric emergency (after punishable sexual acts in two cases). In each case, this episode had been preceded by an increase of self-administered apomorphine, whereas other antiparkinsonian drugs remained unchanged. Questioning had revealed psychosexual disturbances as early as the onset of apomorphine treatment, which tended to progressively worsen with the number of apomorphine daily doses. A decrease in the dosage of apomorphine had been followed by the improvement of the psychiatric condition without worsening of the motor status. Recurrence of psychiatric disorders with similar features had been observed when two patients again increased the number of apomorphine daily injections. The absence of somatic manifestations when apomorphine treatment was withdrawn or reduced, with persistence of psychosexual disturbances, could suggest a psychological dependence from the drug.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9099466</PMID><DateCreated><Year>1997</Year><Month>06</Month><Day>18</Day></DateCreated><DateCompleted><Year>1997</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>1997</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>140-7</MedlinePgn></Pagination><Abstract><AbstractText>A similar pattern of psychosexual disorders has been observed after long-term treatment with levodopa therapy in four male parkinsonian patients treated with apomorphine for severe on-off motor fluctuations. An acute episode in each case had led them to the hospital in the context of a psychiatric emergency (after punishable sexual acts in two cases). In each case, this episode had been preceded by an increase of self-administered apomorphine, whereas other antiparkinsonian drugs remained unchanged. Questioning had revealed psychosexual disturbances as early as the onset of apomorphine treatment, which tended to progressively worsen with the number of apomorphine daily doses. A decrease in the dosage of apomorphine had been followed by the improvement of the psychiatric condition without worsening of the motor status. Recurrence of psychiatric disorders with similar features had been observed when two patients again increased the number of apomorphine daily injections. The absence of somatic manifestations when apomorphine treatment was withdrawn or reduced, with persistence of psychosexual disturbances, could suggest a psychological dependence from the drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Courty</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zenut</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Courty</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lavarenne</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062787" MajorTopicYN="N">Drug Overdose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020018" MajorTopicYN="N">Sexual Dysfunctions, Psychological</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9099466</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001536 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001536 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9099466
|texte= Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9099466" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |